{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:56:32Z","timestamp":1762322192815,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1159579","GNT2007007","GNT1184428"],"award-info":[{"award-number":["GNT1159579","GNT2007007","GNT1184428"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ijantimicag.2025.107488","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T23:35:30Z","timestamp":1741304130000},"page":"107488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3850-1555","authenticated-orcid":false,"given":"J.R.","family":"Tait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Agyeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"L\u00f3pez-Causap\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-3823","authenticated-orcid":false,"given":"D.","family":"Deveson-Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4608-8744","authenticated-orcid":false,"given":"R.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.E.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.S.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8590","authenticated-orcid":false,"given":"R.L.","family":"Nation","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4743","authenticated-orcid":false,"given":"C.B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107488_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40168-020-00810-3","article-title":"Lung function and microbiota diversity in cystic fibrosis","volume":"8","author":"Cuthbertson","year":"2020","journal-title":"Microbiome"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0002","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.23036","article-title":"Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis","volume":"50","author":"Zemanick","year":"2015","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0003","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1126\/science.288.5469.1251","article-title":"High frequency of hypermutable pseudomonas aeruginosa in cystic fibrosis lung infection","volume":"288","author":"Oliver","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0004","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijmm.2010.08.009","article-title":"Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy","volume":"300","author":"Oliver","year":"2010","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0006","article-title":"Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis","author":"Holland","year":"2021","journal-title":"Cochrane Database of Syst Rev"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0007","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0008","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/QCO.0000000000000217","article-title":"Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis","volume":"28","author":"Langan","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0009","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ppul.20985","article-title":"A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis","volume":"44","author":"Van Meter","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ppul.21467","article-title":"A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients","volume":"46","author":"Zobell","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0012","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/S2666-5247(22)00121-5","article-title":"Research priorities towards precision antibiotic therapy to improve patient care","volume":"3","author":"Bulman","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0013","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.770518","article-title":"Limitations of antibiotic MIC-based PK-PD metrics: looking back to move forward","volume":"12","author":"Landersdorfer","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.xphs.2023.10.029","article-title":"Distinguishing inducible and non-inducible resistance to colistin in pseudomonas aeruginosa by quantitative and systems pharmacology modeling at low and standard inocula","volume":"113","author":"Bulitta","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0016","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cmi.2024.06.026","article-title":"The effects of single and multiple resistance mechanisms on bacterial response to meropenem","volume":"30","author":"Fuhs","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0017","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cmi.2017.12.004","article-title":"Assessment and modelling of antibacterial combination regimens","volume":"24","author":"Rao","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0018","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/cpt.2182","article-title":"Pivotal role of translation in anti-infective development","volume":"109","author":"Friberg","year":"2021","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02142-19","article-title":"Hypermutator pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients","volume":"64","author":"Colque","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02055-17","article-title":"Optimization of a meropenem-tobramycin combination dosage regimen against hypermutable and nonhypermutable Pseudomonas aeruginosa via mechanism-based modeling and the hollow-fiber infection model","volume":"62","author":"Landersdorfer","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jgar.2021.04.021","article-title":"Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model","volume":"26","author":"Tait","year":"2021","journal-title":"J Global Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00414-23","article-title":"Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and heteroresistance","volume":"67","author":"Tait","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0023","doi-asserted-by":"crossref","first-page":"e02538","DOI":"10.1128\/AAC.02538-18","article-title":"Characterization of hypermutator Pseudomonas aeruginosa isolates from patients with cystic fibrosis in Australia","volume":"63","author":"Rees","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"year":"2023","series-title":"Performance standards for antimicrobial susceptibility testing, 33rd ed. CLSI supplement M100","key":"10.1016\/j.ijantimicag.2025.107488_bib0024"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000063216","article-title":"Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients","volume":"47","author":"Bui","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","article-title":"Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis","volume":"52","author":"Hennig","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0027","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/AAC.01713-15","article-title":"Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0028","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(99)70103-7","article-title":"Tobramycin penetration into epithelial lining fluid of patients with pneumonia","volume":"65","author":"Carcas","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0029","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0030","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0031","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jac\/dku354","article-title":"Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study","volume":"70","author":"Frippiat","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0033","article-title":"The hollow fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics","volume":"S1","author":"Cadwell","year":"2012","journal-title":"Adv Pharmacoepidem Drug Safety"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0034","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jcf.2011.05.002","article-title":"Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?","volume":"10","author":"Stressmann","year":"2011","journal-title":"J Cyst Fibrosis"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0035","series-title":"Antibiotics in laboratory medicine","article-title":"Antibiotic combinations","author":"Pillai","year":"2005"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02121-16","article-title":"Polymyxin B in combination with rifampin and meropenem against polymyxin B-resistant KPC-producing Klebsiella pneumoniae","volume":"61","author":"Diep","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0037","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1208\/s12248-011-9257-x","article-title":"Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT","volume":"13","author":"Bulitta","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0038","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1208\/s12248-011-9258-9","article-title":"Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models","volume":"13","author":"Bulitta","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0039","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1128\/AAC.00881-09","article-title":"Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model","volume":"54","author":"Bulitta","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.ijantimicag.2025.107488_bib0040","doi-asserted-by":"crossref","first-page":"S513","DOI":"10.1093\/cid\/cir166","article-title":"Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead","volume":"52","author":"Tsuji","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0041","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0042","doi-asserted-by":"crossref","first-page":"e0003622","DOI":"10.1128\/mmbr.00036-22","article-title":"Aminoglycoside uptake, stress, and potentiation in Gram-negative bacteria: new therapies with old molecules","volume":"87","author":"Lang","year":"2023","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0043","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1128\/AAC.00507-08","article-title":"Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa","volume":"52","author":"Schurek","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0044","article-title":"Gene Expression Profiling of Pseudomonas aeruginosa Upon Exposure to Colistin and Tobramycin","volume":"12:626715","author":"Cianciulli Sesso","year":"2021","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0045","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.39.9.1948","article-title":"Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa","volume":"39","author":"Li","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0046","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/AAC.43.2.424","article-title":"Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems","volume":"43","author":"K\u00f6hler","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0047","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1128\/AAC.00196-16","article-title":"Sequential treatment of biofilms with aztreonam and tobramycin is a novel strategy for combating Pseudomonas aeruginosa chronic respiratory infections","volume":"60","author":"Rojo-Molinero","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0048","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01024-08","article-title":"Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients","volume":"53","author":"Vettoretti","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0049","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1128\/JB.185.20.6195-6198.2003","article-title":"Mutations affecting DNA-binding activity of the MexR repressor of mexR-mexA-mexB-oprM operon expression","volume":"185","author":"Saito","year":"2003","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0050","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.5b01098","article-title":"Targeting the bacterial division protein FtsZ","volume":"59","author":"Hurley","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0051","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1128\/jb.173.11.3500-3506.1991","article-title":"ftsZ is an essential cell division gene in Escherichia coli","volume":"173","author":"Dai","year":"1991","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0052","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1128\/AAC.05829-11","article-title":"PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients","volume":"56","author":"Moskowitz","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0053","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2958.2003.03673.x","article-title":"Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa","volume":"50","author":"McPhee","year":"2003","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0054","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01044-19","article-title":"Production of norspermidine contributes to aminoglycoside resistance in pmrAB mutants of Pseudomonas aeruginosa","volume":"63","author":"Bolard","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/JB.186.2.575-579.2004","article-title":"PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A","volume":"186","author":"Moskowitz","year":"2004","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0056","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02583-17","article-title":"Evolution of the Pseudomonas aeruginosa aminoglycoside mutational resistome in vitro and in the cystic fibrosis setting","volume":"62","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0057","article-title":"Aminoglycoside concentrations required for synergy with carbapenems against Pseudomonas aeruginosa determined via mechanistic studies and modeling","volume":"61","author":"Yadav","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0058","doi-asserted-by":"crossref","first-page":"e0316523","DOI":"10.1128\/mbio.03165-23","article-title":"Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa","volume":"15","author":"Farrington","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0059","first-page":"387","article-title":"Proof-of-concept for incorporating mechanistic insights from multi-omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae","volume":"12","author":"Hanafin","year":"2023","journal-title":"CPT: Pharmacometrics & Syst Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004782","article-title":"Distinguishing antimicrobial models with different resistance mechanisms via population pharmacodynamic modeling","volume":"12","author":"Jacobs","year":"2016","journal-title":"PLOS Comput Biol"},{"issue":"11","key":"10.1016\/j.ijantimicag.2025.107488_bib0061","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01150-18","article-title":"Meropenem combined with ciprofloxacin combats hypermutable Pseudomonas aeruginosa from respiratory infections of cystic fibrosis patients","volume":"62","author":"Rees","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0062","doi-asserted-by":"crossref","DOI":"10.1099\/mic.0.001361","article-title":"Preclinical testing of antimicrobials for cystic fibrosis lung infections: current needs and future priorities","volume":"169","author":"Hubert","year":"2023","journal-title":"Microbiology (Reading)"},{"issue":"1","key":"10.1016\/j.ijantimicag.2025.107488_bib0063","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01679-19","article-title":"Meropenem-tobramycin combination regimens combat carbapenem-resistant Pseudomonas aeruginosa in the hollow-fiber infection model simulating augmented renal clearance in critically ill patients","volume":"64","author":"Yadav","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0064","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-19","article-title":"Synergistic meropenem-tobramycin combination dosage regimens against clinical hypermutable Pseudomonas aeruginosa at simulated epithelial lining fluid concentrations in a dynamic biofilm model","volume":"63","author":"Bilal","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107488_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:40:48Z","timestamp":1762321248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0924857925000457"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107488","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiomics informed mathematical model for meropenem and tobramycin against hypermutable Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107488"}}